| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other expense, net | -1,901 | -1,306 | -1,612 | -2,156 |
| Net loss | -274 | 204 | -9,742 | -22,860 |
| Net loss per share, basic (in dollars per share) | -0.03 | 0.02 | -0.1 | -0.49 |
| Net loss per share, diluted (in dollars shares) | -0.03 | 0.02 | -0.1 | -0.49 |
| Weighted-average common shares outstanding, basic (in shares) | 9,490,083 | 9,488,055 | 94,837,343 | 46,805,427 |
| Weighted-average common shares outstanding, diluted (in shares) | 9,490,083 | 9,490,600 | 94,837,343 | 46,805,427 |
Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. (VRCA)